Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Lenalidomide in Relapsed or Refractory Peripheral T-cell Lymphoma
NCT04329130Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04329130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04329130.